Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests

Journal of Rheumatology

Volumn 41, Issue 7, 2014, Pages 1334-1343

  Mahler, Michael ^a   Satoh, Minoru ^b,c   Hudson, Marie ^d   Baron, Murray ^d   Chan, Jason Y F ^e   Chan, Edward K L ^e   Wick, James ^f   Fritzler, Marvin J ^f  

^a INOVA DIAGNOSTICS INC   (United States)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

Autoantibodies; Elisa; Indirect immunofluorescence; Systemic sclerosis; Th To

Indexed keywords

ANTIGEN; ANTINUCLEAR ANTIBODY; CELL NUCLEUS ANTIGEN; EXTRACTABLE NUCLEAR ANTIGEN; GLYCINE DEHYDROGENASE (DECARBOXYLATING); RIBONUCLEASE P; RIBONUCLEASE P PROTEIN SUBUNIT P25; TH ANTIGEN; TO ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIBODY; PROTEIN SUBUNIT;

ADULT; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHEMILUMINESCENCE IMMUNOASSAY; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SYSTEMIC SCLEROSIS; TH/TO ANTIGEN COMPLEX; AGED; IMMUNOLOGY; MIDDLE AGED; PROTEIN SUBUNIT;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN SUBUNITS; RIBONUCLEASE P; SCLERODERMA, SYSTEMIC;

EID: 84903702366     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131450     Document Type: Article

References (43)

1. Mahler M, Fritzler MJ. Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 2010; 1183:267-87.
2. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12:340-54.
3. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? Autoimmun Rev 2010;9:756-60.
4. Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011;10:194-200.
5. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737-47.
6. Mahler M, Raijmakers R. Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun Rev 2007;6:432-7. (Pubitemid 47069969)
7. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)
8. Arnett FC, Reveille JD, Goldstein R, Pollard KM, Leaird K, Smith EA, et al. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39:1151-60. (Pubitemid 26240228)
9. Ceribelli A, Cavazzana I, Franceschini F, Airo P, Tincani A, Cattaneo R, et al. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. J Rheumatol 2010;37:2071-5.
10. Van Eenennaam H, Vogelzangs JH, Lugtenberg D, Van Den Hoogen FH, Van Venrooij WJ, Pruijn GJ. Identity of the RNase MRP-and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002;46:3266-72. (Pubitemid 35453536)
11. Van Eenennaam H, Vogelzangs JH, Bisschops L, Te Boome LC, Seelig HP, Renz M, et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002;130:532-40. (Pubitemid 35418339)
12. Okano Y, Medsger TA Jr. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990;33:1822-8.
13. Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, Wright TM, Curran-Everett D, West SG, et al. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006;33:1600-5. (Pubitemid 44168833)
14. Wiik AS, Hoier-Madsen M, Forslid J, Charles P, Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010;35:276-90.
15. Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15:102-9.
16. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. Arthritis Res Ther 2011;13:R172.
17. Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002;61:842-6.
18. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007;9:R78.
19. Mahler M, Gascon C, Patel S, Ceribelli A, Fritzler MJ, Swart A, et al. Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. Arthritis Res Ther 2013;15:R50.
20. Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012;12:114-20.
21. Bonroy C, Van Praet J, Smith V, Van Steendam K, Mimori T, Deschepper E, et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods 2012;379:53-60.
22. Ceribelli A, Satoh M, Chan EK. A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. Arthritis Res Ther 2012;14:R128.
23. Hudson M, Satoh M, Chan JY, Tatibouet S, Mehra S, Baron M, et al; Canadian Scleroderma Research Group A (CSRG). Prevalence and clinical profiles of "autoantibody-negative" systemic sclerosis subjects. Clin Exp Rheumatol 2013 Oct 21 (E-pub ahead of print).
24. Muro Y, Sugiura K, Akiyama M. What autoantibody tests should become widely available to help scleroderma diagnosis and management? Arthritis Res Ther 2013;15:116.
25. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther 2012;14:R50.
26. Mahler M, You D, Baron M, Taillefer SS, Hudson M, Fritzler MJ. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 2011;412:1937-43.
27. Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta 2012;413:719-26.
28. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8. (Pubitemid 29003722)
29. Satoh M, Vazquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 2009;19:219-28.
30. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol 2012;2012:494356.
31. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319-27.
32. Op De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D, et al. Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev 2012;12:137-43.
33. Parker JC, Bunn CC. Sensitivity of the Phadia EliA connective tissue disease screen for less common disease-specific autoantibodies. J Clin Pathol 2011;64:631-3.
34. Shanmugam VK, Swistowski DR, Saddic N, Wang H, Steen VD. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol 2011;30:1363-8.
35. Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EK, Bubb MR, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol 2011; 30:1333-9.
36. Jakymiw A, Ikeda K, Fritzler MJ, Reeves WH, Satoh M, Chan EK. Autoimmune targeting of key components of RNA interference. Arthritis Res Ther 2006;8:R87.
37. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To-and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9. (Pubitemid 36091664)
38. Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007;19:580-91. (Pubitemid 47530879)
39. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008;58:3902-12.
40. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73:17-23.
41. Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012;71:1355-60.
42. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13:R211.
43. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63. (Pubitemid 46846694)